Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib

1. Paz-Ares, L.
2. García Del Muro, X.
3. Grande, E.
4. González, P.
5. Brosa, M.
6. Díaz, S.